Downregulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathway

ZHENG-CAI JIANG¹, XIAO-JUN CHEN², QI ZHOU², XIAO-HUA GONG², XIONG CHEN² and WEN-JUN WU²

¹Department of General Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000; ²Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China

Received March 13, 2018; Accepted April 1, 2019

DOI: 10.3892/ijo.2019.4816

Abstract. Emerging studies have indicated that leucine-rich repeat kinase 2 (LRRK2) is associated with thyroid cancer (TC). The present study investigated the effect of LRRK2 on the cell cycle and apoptosis in TC, and examined the underlying mechanisms in vitro. To screen TC-associated differentially expressed genes, gene expression microarray analysis was conducted. Retrieval of pathways associated with TC from the Kyoto Encyclopedia of Genes and Genomes database indicated that the c-Jun N-terminal kinase (JNK) signaling pathway serves an essential role in TC. SW579, IHH-4, TFC-133, TPC-1 and Nthy-ori3-1 cell lines were used to screen cell lines with the highest and lowest LRRK2 expression for subsequent experiments. The two selected cell lines were transfected with pcDNA-LRRK2, or small interfering RNA against LRRK2 or SP600125 (a JNK inhibitor). Subsequently, flow cytometry, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling, a 5-ethynyl-2'-deoxyuridine assay and a scratch test was conducted to detect the cell cycle distribution, apoptosis, proliferation and migration, respectively, in each group. The LRRK2 gene was determined to be elevated in TC based on the microarray data of the GSE3678 dataset. The SW579 cell line was identified to exhibit the highest LRRK2 expression, while IHH-4 cells exhibited the lowest LRRK2 expression. LRRK2 silencing, through inhibiting the activation of the JNK signaling pathway, increased the expression levels of genes and proteins associated with cell cycle arrest and apoptosis in TC cells, promoted cell cycle arrest and apoptosis, and inhibited cell migration and proliferation in TC cells, indicating that LRRK2 repression could exert beneficial effects through the JNK signaling pathway on TC cells. These observations demonstrate that LRRK2 silencing promotes TC cell growth inhibition, and facilitates apoptosis and cell cycle arrest. The JNK signaling pathway may serve a crucial role in mediating the anti-carcinogenic activities of downregulated LRRK2 in TC.

Introduction

As a common endocrine-associated malignancy, thyroid cancer (TC) typically arises from thyroid nodules, which can be detected by palpation and imaging in adults, particularly in the elderly (1,2). TC with different cellular origins, characteristics and prognoses possess different histological types and subtypes (3). There are numerous risk factors for TC, including ionizing radiation exposure, a history of benign thyroid disease and a family history of TC (4‑6). TC has been reported to account for 1.0‑1.5% of new cancer cases diagnosed each year in USA, and its incidence has steadily increased in the last 30 years up to 2013 (7). According to a statistic reported in 2015, TC is the most commonly diagnosed cancer among females who are >30 years old in China (8). No notable symptoms occur during the life of the patient with TC; therefore, TC is frequently firstly identified in an autopsy finding (9). TC afflicts patients due to its chronic nature, and patients require life-long medication or monitoring (10). Further effective diagnoses and treatments of TC remain a topic of research (11,12). Gene therapy is considered to be the most promising novel method in the treatment of dire cases of TC and those that do not respond to traditional treatments (13).

The leucine-rich repeat kinase 2 (LRRK2) gene encodes a large protein with a domain such as a Ras complex guanosine triphosphate hydrolyase domain and a C-terminal Roc domain (14). The LRRK2 expression has been detected in various regions, including the substantia nigra, putamen, cortex and cerebellum, and has been demonstrated to be responsible for autosomal-dominant Parkinson's disease (PD) (15‑18). Furthermore, a previous study reported that LRRK2 is
overexpressed in TC, and its expression is a relatively specific marker for TC (19). Additionally, as a highly conserved pathway, the c-Jun N-terminal kinase (JNK) signaling pathway functions crucially in regulating gene expression and intracellular metabolism in life activities, including growth and development, apoptosis and cellular response to external stress (20). Recently, the activation of the JNK signaling pathway was reported to mediate thyroid dysfunction resulting from thyroid inflammatory responses and polychlorinated biphenyls (21). Based on existing knowledge, gene expression microarray analysis was performed to screen differentially expressed genes (DEGs) associated with TC and determine an unclarified gene, LRRK2, associated with TC. Hereby, attempts were undertaken in the present study to investigate the potential association among LRRK2, the JNK signaling pathway and TC in two selected TC cell lines. However, the effect of LRRK2 on human TC cells is vague. In the present study, the potential mechanism of LRRK2 in human TC cells was elucidated from the effects of LRRK2 on the cell cycle and apoptosis of TC cells. An association was determined between LRRK2 and JNK signaling pathways. The present experimental results indicated that LRRK2 affects the cell cycle arrest and apoptosis of TC cells due to its involvement in the JNK signaling pathway.

Materials and methods

Bioinformatics prediction. The Gene Expression Omnibus (GEO; (https://www.ncbi.nlm.nih.gov/gds/?term=thyroid+ cancer)) database was used to retrieve data with ‘thyroid cancer’ as the keyword, and GSE3678 microarray dataset (22) were selected using GPL570. The annotated probe files included 7 TC samples and 7 healthy control samples. With the significant threshold (|log2FC| > 2, P<0.05), DEGs were selected using the Limma and cultured for 6‑8 h at 37˚C in an atmosphere containing 5% CO₂. According to the cell growth conditions, when the cells were spread over 80‑90% of the culture plate, the cells were passaged. The two cell lines with the highest and lowest LRRK2 expression levels were selected for subsequent experiments via reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis according to the subsequent protocols.

Plasmid construction, cell grouping and transfection. According to the known sequences of LRRK2 in the National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/nuccore/XM_005268629.4/), negative control (NC), overexpression and three interference sequences (Table I) were constructed by Sangon Biotechnology Co., Ltd. (Shanghai, China), and were synthesized by Shanghai GeneChem Co., Ltd. (Shanghai, China). RT‑qPCR and western blot analysis were performed, according to the subsequent protocols, to select an interference sequence with the best interference efficacy following SW579 cell transfection, according to the subsequent protocols, for further usage.

The SW579 and IHH‑4 cell lines in the logarithmic growth phase were digested with trypsin and seeded in a 24‑well plate at a cell density of 1x10⁵ cells/ml. The cells were assigned into the blank (transfected with negative plasmids), NC (transfected with unrelated plasmid), pcDNA‑LRRK2 (transfected with pcDNA‑LRRK2 plasmid), si‑LRRK2 [transfected with small interfering (si)RNA against LRRK2], SP600125 (transfected with a JNK inhibitor), and si‑LRRK2 and SP600125 (co‑transfected with si‑LRRK2 plasmid and SP600125 plasmid) groups. These plasmids were provided by Sangon Biotechnology Co., Ltd.

The cells were transfected with Lipofectamine® 2000, according to the manufacturer's protocols (cat. no. 11668‑019; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). A total of 250 µl Option‑MEM without serum (cat. no. 51985042; Gibco; Thermo Fisher Scientific, Inc.) was used to dilute 100 pmol plasmids to a final concentration of 50 nM, followed by incubation at room temperature for 5 min with gentle shaking. A total of 250 µl Option‑MEM without serum was used to dilute 5 µl Lipofectamine 2000, followed by incubation at room temperature for 5 min with gentle shaking. A mixture of the aforementioned two solutions, following incubation at room temperature for 20 min, was seeded in a culture well at a cell density of 1x10⁶ cells/well and cultured for 6‑8 h at 37˚C in an atmosphere containing 5% CO₂. The medium was replaced with fresh RPMI‑1640 complete medium, and the cells were continuously cultured at 37˚C for 24‑48 h for subsequent experiments.

RT‑qPCR. miRNeasy Mini kit (cat. no. 217004; Qiagen GmbH, Hilden, Germany) were used to extract total RNA from the two TC cell lines, according to the manufacturer's protocols. Primers
Table I. Sequences of three siRNA.

<table>
<thead>
<tr>
<th>siRNA</th>
<th>Sequence (DNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>si-LRRK2-1</td>
<td>5'-TACGTCAGCACGTCGGCCAGGGAAG-3'</td>
</tr>
<tr>
<td>si-LRRK2-2</td>
<td>5'-GCTACTTCTATCTACAGCTC-3'</td>
</tr>
<tr>
<td>si-LRRK2-3</td>
<td>5'-GGATCTCCTCTTTATTAAT-3'</td>
</tr>
<tr>
<td>NC</td>
<td>5'-GCTTGGATGCGCTAGGTGA-3'</td>
</tr>
</tbody>
</table>

siRNA, small interfering RNA; LRRK2, leucine-rich repeat kinase 2; NC, negative control.

(Table II) were synthesized by Takara Biotechnology Co., Ltd. (Dalian, China). RNA was reverse transcribed into cDNA using PrimeScript RT kit (cat. no. RR036A; Takara Biotechnology Co., Ltd.). The reverse transcription system was conducted as follows: Reverse transcription reaction for 15 min at 37°C (three times) and reverse transcriptase inactivation reaction at 85°C for 5 sec. qPCR was conducted according to the instructions of the SYBR® Premix Ex Taq™ II kit (cat. no. RR820A; Takara Biotechnology Co., Ltd.). The reaction system (50 μl) contained 25 μl SYBR Premix Ex Taq II (2X), 2 μl forward primer for PCR, 2 μl reverse primer for PCR, 1 μl Ox Reference Dye (50X), 4 μl DNA template and 16 μl double-distilled H2O. The ABI 7500 qPCR instrument (cat. no. 7500; Applied Biosystems; Thermo Fisher Scientific, Inc.) was employed for qPCR detection. The qPCR conditions were as follows: Pre-denaturation at 95°C for 30 sec, 40 cycles of denaturation at 95°C for 5 sec, and annealing and extension at 60°C for 30 sec. With 2 μg total RNA as the template and GAPDH as the internal reference, the relative mRNA expression of target genes was calculated based on the 2^(-ΔΔCq) method, \( \Delta\Delta Cq = (Cq_{target \ gene} - Cq_{reference \ gene \ in \ the \ model \ group}) - (Cq_{target \ gene} - Cq_{reference \ gene \ in \ the \ control \ group}) \) (26). The experiment was independently repeated in triplicate.

Western blot analysis. Cells in the logarithmic growth phase were centrifuged at 5,035 x g for 20 min at 4°C. Every 20 μl, packed cells were added to 100 μl lysis and 1 μl enzyme inhibitor (cat. no. 1111111; Jiamay Biotech, Ltd., Beijing, China), lysed on ice for 30 min and centrifuged at 16,000 x g at 4°C for 10 min. Thereafter, the supernatant proteins were extracted for protein quantitative detection using a Coomassie brilliant blue protein assay. A total of 50 μg proteins were extracted to be dissolved in 2X SDS sample buffer (Thermo Fisher Scientific, Inc.) followed by blocking with 5% non-fat milk powder at room temperature for 30 min, were transferred to the polyvinylidene fluoride (PVDF) membrane via 10% SDS-PAGE, followed by blocking with 5% non-fat milk powder at room temperature for 1 h and washing 2 times with PBS. Subsequently, the PVDF membrane was cultured overnight at 4°C with diluted primary antibodies of mouse anti-human purchased from Abcam (Cambridge, UK), including LRRK2 (1:20,000; cat. no. ab133474), JNK (1:2,000; cat. no. ab124956), phospho(p)-JNK (1:500; cat. no. ab59196), matrix metalloproteinase (MMP-9; 1:5,000; cat. no. ab73734), Cyclin A2 (1:2,000; cat. no. ab181591), Cyclin D1 (1:20,000; cat. no. ab31475), B-cell lymphoma 2 (Bcl-2)-associated X (Bax; 1:5000; cat. no. ab32503), Bcl-2 (1:1,000; cat. no. ab32124), p16 (1:5,000; cat. no. ab51243), cyclin-dependent kinase 4 (CDK4; 1:5,000; cat. no. ab108357) and GAPDH (1:1,000; cat. no. ab8245). Following washing in TBS with 0.05% Tween-20 (TBST) three times (5 min each), the membrane was incubated at room temperature for 1 h with diluted secondary antibodies of goat anti-rat (1:100) labeled with horseradish peroxidase (cat. no. HA1003; Yan Hui Biological Technology Co., Ltd., Shanghai, China). The membrane was reacted with enhanced chemiluminescence (cat. no. ECL808-25; Biomiga, Inc., San Diego, CA, USA) at room temperature for 1 min. Following discarding the liquids, the membrane was covered with a preservative film, followed by X-ray imaging (cat. no. 36209JES01; Shanghai Qbio Science & Technologies Co., Ltd., Shanghai, China) and was observed. Using GAPDH as the internal reference, the relative protein expression was equal to the ratio of target protein bands and internal reference bands. The experiment was independently repeated in triplicate.

5-ethynyl-2'-deoxyuridine (EdU) assay. Cells were incubated in a cell culture plate at a density of 1x10^5 cells/ml with EdU solution (Beijing Biolab Technology Co., Ltd., Beijing, China) at room temperature for 2 h and were washed once with PBS. Thereafter, the cells were fixed with 40 g/l polyoxymethylene at room temperature for 30 min, were

Table II. Primer sequences for reverse transcription quantitative polymerase chain reaction.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primers sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRRK2</td>
<td>F: GGAATCCCAACACTGGACA</td>
</tr>
<tr>
<td></td>
<td>R: GGTAGCGTCGCTGAAGCACA</td>
</tr>
<tr>
<td>JNK</td>
<td>F: CAAAGCAGTGTAGATGAAAGGGA</td>
</tr>
<tr>
<td></td>
<td>R: CAGACGACGATGATGAGTGA</td>
</tr>
<tr>
<td>MMP-9</td>
<td>F: ACCACGACCAACCTCACAC</td>
</tr>
<tr>
<td></td>
<td>R: CACCAGCTGATGCAATGAGT</td>
</tr>
<tr>
<td>Cyclin A2</td>
<td>F: ATGTCCACGGTTCTCTCTTTG</td>
</tr>
<tr>
<td></td>
<td>R: GGCCATTTCTACCGTCTATT</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>F: CCCTCGTTGCTCTACTTTCA</td>
</tr>
<tr>
<td></td>
<td>R: CTCCTCAGCTTCTTGGTCTT</td>
</tr>
<tr>
<td>Bax</td>
<td>F: ATGGGCTGACATGGACAGT</td>
</tr>
<tr>
<td></td>
<td>R: GGGAATCAGTGCTGCTCAGT</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>F: CAACACACAGACCCACCCAGA</td>
</tr>
<tr>
<td></td>
<td>R: TGGCTTCATAACACAGTTTC</td>
</tr>
<tr>
<td>p16</td>
<td>F: CATCCCCGATTGAAAGAACC</td>
</tr>
<tr>
<td></td>
<td>R: AATGGACATTTACGGTATGTG</td>
</tr>
<tr>
<td>CDK4</td>
<td>F: AAATCTTTGACCTGACCTG</td>
</tr>
<tr>
<td></td>
<td>R: CCTTATGATAGAAGTGCTG</td>
</tr>
<tr>
<td>GAPDH</td>
<td>F: GGAAAACGTGTGGCGCTGAT</td>
</tr>
<tr>
<td></td>
<td>R: GAGTGGGTGTGCCTGTGGA</td>
</tr>
</tbody>
</table>

LRRK2, leucine-rich repeat kinase 2; JNK, c-Jun N-terminal kinase; MMP-9, matrix metalloproteinase-9; CDK4, cyclin-dependent kinase 4; F, forward; R, reverse; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X.
incubated in glycine solution at room temperature for 8 min and were washed two times with PBS, followed by rinsing with PBS containing 0.5% Triton X-100. After adding Apollo® staining solution (Shanghai Threebio Technology Co., Ltd., Shanghai, China), cells were incubated avoiding light at room temperature for 30 min and then were observed under a fluorescence microscope (x400 magnification). EdU-stained cells (proliferating cells) and Hoechst 33342-stained cells (total cells; stained at 37°C for 90 min) were counted in three fields selected in 400-fold fields as follows: Cell proliferation rate = (proliferated cells / total cells) x 100%. The experiment was independently repeated in triplicate.

Flow cytometry. After 48 h of transfection, the cells were collected and reacted with 0.25% trypsin. The cell density was adjusted to 1x10⁶ cells/ml in fresh RPMI-1640 complete medium. A total of 1 ml cells was centrifuged at 5,440 x g for 10 min at 37°C. Following removal of the supernatant, 1 ml PBS was added to 2 ml PBS, followed by centrifugation at 5,440 x g for 15 min at 37°C. The supernatant was discarded, and the cells were fixed overnight at 4°C with an addition of 70% ethanol. The following day, the cells were washed with PBS twice. The cell suspension (100 µl) was added to 50 µg propidium iodide (PI) containing RNase (cat. no. 40710ES03; Shanghai Qbio Science & Technologies Co., Ltd.), avoiding light at room temperature for 15 min. Following the addition of 300 µl binding buffer (cat. no. ab14085; Abcam) and 5 µl PI, the cells were gently mixed and reacted avoiding light at room temperature for 30 min, and then was filtered using a nylon mesh with 100 meshes. A flow cytometer (BD Bioscience; Beckman Coulter, Inc., Franklin Lakes, NJ, USA) was employed to record the red fluorescence at an excitation wavelength of 488 nm to detect the cell cycle distribution.

Annexin V-fluorescein isothiocyanate/PI (FITC/PI) double staining was conducted to detect cell apoptosis. The treated cells were cultured at 37°C in an incubator containing 5% CO₂ for 48 h. Subsequently, the cells were collected and washed twice with PBS, followed by centrifugation at 5,053 x g for 10 min at 37°C and suspension in 200 µl binding buffer (Shanghai Canspec Scientific Instruments Co., Ltd., Shanghai, China). Following the addition of 10 µl Annexin V-FITC (cat. no. ab14085; Abcam) and 5 µl PI, the cells were gently mixed and reacted avoiding light at room temperature for 15 min. Following the addition of 300 µl binding buffer (Shanghai Canspec Scientific Instruments Co., Ltd.), the flow cytometer (BD Bioscience; Beckman Coulter, Inc.) was used to detect cell apoptosis at an excitation wavelength of 488 nm. The experiment was independently repeated in triplicate.

Scratch test. After 48 h of transfection, the transfected cells were seeded in a 6-well plate with 5x10³ cells/well. When the cell confluence reached ~90% at room temperature, a thin wound was produced along the center of each well via a 10 µl sterile pipette tip. Following removal of floating cells by PBS, the cells continued to be cultured with serum-free medium. A total of 2x10⁵ single cell suspension/ml was inoculated in the 24-well plate with pretreated coverslips at room temperature for 24 h. Subsequently, the medium was replaced, and each culture was set up in a sextuplet manner. A total of 300 µl cells were added to RPMI-1640 culture medium, followed by culture at room temperature for 48 h. Thereafter, the cells were stained and mounted according to the manufacturer's protocols. The cells were then observed and imaged under a fluorescence microscope (x400 magnification; cat. no. M30C; Shanghai Wanheng Precision Instrument Co., Ltd.) with an excitation wavelength of 350 nm and an emission wavelength of 460 nm.

Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). A total of 2x10⁵ single cell suspension/ml was inoculated in the 24-well plate with pretreated cover glass and cultured at room temperature for 24 h. Subsequently, the serum-free medium (LONZA X-VIVO was changed, and the cells were fixed with 4% polyformaldehyde at 4°C for 30 min, washed with PBS once, resuspended with PBS (3:1,000) containing 0.3% Triton X-100, and incubated at room temperature for 5 min. Cells were stained and mounted with neutral balsam based on the instructions of TUNEL apoptosis detection kit (cat. no. C1088; Beyotime Institute of Biotechnology, Shanghai, China). Subsequently, the cells were observed and imaged under a fluorescence microscope (10 random fields; x400 magnification; cat. no. M30C; Shanghai Wanheng Precision Instruments Co., Ltd.) when the excitation wavelength was 450 nm and emission wavelength was 565 nm (green fluorescence).

Sulforhodamine B (SRB) staining. Cells in the logarithmic growth phase were collected and diluted by RPMI-1640 culture medium to 1x10⁶ cells/ml cell suspension. The suspension was injected into a 96-well plate using a Finnpipette (Thermo Fisher Scientific, Inc.) with 190 µl in each well. The cells were then cultured at 37°C in an atmosphere containing 5% CO₂, and after 24, 48 or 72 h culturing, 0.1 g/l trichloroacetic acid was added to the cells, followed by fixation at 4°C for 1 h. The cells were washed with distilled water four times. Subsequently, the cells were air dried at room temperature for 20 min and then were placed at room temperature for 30 min of culture with 100 µl SRB (0.1 g/l containing 0.01% acetic acid). The cells were washed with 1% acetic acid four times. After air drying and adding 0.01% Tris base (pH 10.5; 10 mmol/l) alkali liquor containing 200 µl acetic acid, the cells were mixed with oscillation for 3 min, and the optical density (OD) at 579 nm was measured. Inhibition effects on cell growth after 24, 48 or 72 h were observed under an inverted microscope (x400 magnification). Cell growth curves were drawn with time points as the abscissa and the OD value as the ordinate.

Trypan blue staining. To examine whether SP600125 (JNK phosphokinase inhibitor) is toxic to cells, trypan blue staining was used. Through trypan blue staining, SP600125 (1 and 10 µM) was used to treat SW579 cells for 24 h at 37°C. Hanks solution (AAPR25-250; Guangzhou Peiyu Biological Products Co.,...
Limited trypan blue solution. Subsequently, the cultured adherent cells were added with the mixture [0.5% trypsin: 0.2% ethylenediaminetetraacetic acid (E8040; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China); 1:1], and Hanks solution was added to produce cell suspension, and diluted to $1 \times 10^5$/ml. The suspension was added with trypan blue staining solution (0.1 ml suspension added with a drop of trypan blue staining solution) at room temperature for 3-5 min, placed on a slide, and then observed under a high power inverted microscope (magnification, x40; Olympus Optical Co., Ltd., Tokyo, Japan).

**Statistical analysis.** All data were processed by SPSS 21.0 (IBM Corp., Armonk, NY, USA). Measurement data were expressed as the means ± standard deviation. One-way analysis of variance (ANOVA) was used for comparisons among multiple groups. The normality test of data was performed by the Kolmogorov-Smirnov method, and the post hoc test for the data that were distributed in normality among the groups was conducted by Tukey’s multiple comparisons in one-way ANOVA. The cell viability at different time points was analyzed by repeated measurement variance analysis. P<0.05 was considered to indicate a statistically significant difference.

**Results**

LRRK2 is an upregulated gene and the JNK signaling pathway is an associated pathway in TC cells by microarray profiling and enrichment analysis. The sequencing dataset associated with TC was retrieved in the GEO database, and the GSE3678 database was selected. Following differential expression analysis in the dataset (Fig. 1A), 96 DEGs were obtained, among which 55 were upregulated and 41 were downregulated in TC samples.

To further understand the pathogenesis of TC, genes associated with TC were retrieved in the DisGeNET database. The first 10 genes with a high association with TC were analyzed (Table III). Protein interaction analysis between 96 differentiated expression genes and 10 known genes of TC was conducted using the STRING database (Fig. 1B). The results demonstrated that genes with a high association...
with TC were thyroglobulin (TG), ret proto-oncogene (RET), tumor protein 53 (TP53) and LRRK2, among which TG, RET, and TP53 were known genes associated with TC, but the effect of LRRK on TC remained unclear.

The SW579 cell line has the highest LRRK2 expression, while the IHH-4 cell line has the lowest LRRK2 expression, and si-LRRK2-1 exhibits the best interference effect on LRRK2 expression. According to the results of cell screening by RT-qPCR and western blot analysis (Fig. 2A-C), compared with normal thyroid cell line Nthy-ori3-1, the four human TC cell lines all exhibited a significant reduction in LRRK2 mRNA and protein expression levels (P<0.05). However, the SW579 cell line revealed the highest LRRK2 mRNA and protein expression levels, and the IHH-4 cell line exhibited the lowest. Therefore, the SW579 and IHH-4 cell lines were selected for subsequent experiments.

RT-qPCR and western blot analysis were conducted to detect the LRRK2 mRNA and protein expression levels in three si-LRRK2-transfected cells. The results (Fig. 2D-F) demonstrated that LRRK2 mRNA and protein expression among the three groups were ranked as follows (highest to lowest): si-LRRK2-3, si-LRRK2-2 group and then si-LRRK2-1 group (P<0.05, compared with the si-LRRK2-2 and si-LRRK2-3 groups). These data indicate that the si-LRRK2-1 group had the best interference effect on LRRK2 expression in TC cell lines. Therefore, si-LRRK2-1 was selected for further experiments.

Repression of LRRK2 inhibits the activation of the JNK signaling pathway in TC cells. To determine whether LRRK2 affects JNK, MMP-9, Cyclin A, Cyclin D1, Bcl-2, CDK4, Bax or p16 mRNA expression, RT-qPCR was conducted following transfection, the results of which are depicted in Fig. 3. The blank and NC groups demonstrated no significant differences in LRRK2, JNK, MMP-9, Cyclin A, Cyclin D1, Bcl-2, CDK4, Bax or p16 mRNA expression (all P>0.05). Compared with the blank and NC groups, the pcDNA-LRRK2 group exhibited significantly upregulated mRNA expression levels of LRRK2, JNK, MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4, but significantly downregulated mRNA expression levels of Bax and p16, which was opposite to the tendencies of the si-LRRK2, SP600125 and si-LRRK2 + SP600125 groups (P<0.05). Compared with the expression in the si-LRRK2 group, the mRNA expression levels of LRRK2, JNK, MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4 were significantly decreased, while those of Bax and p16 were significantly increased in the si-LRRK2 + SP600125 group (P<0.05). The results in the SW579 and IHH-4 cell lines demonstrated a consistent tendency. These results provide evidence that LRRK2 silencing could inhibit the activation of the JNK signaling pathway, which in turn, results in increased mRNA expression of Bax and p16 and reduced expression of MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4.

To investigate whether LRRK2 could alter the extent of p-JNK, as well as the protein expression of JNK, MMP-9, Cyclin A, Cyclin D1, Bcl-2, CDK4, Bax and p16 following transfection, western blot analysis was conducted. As depicted in Fig. 4, there was no significant difference observed regarding the protein expression levels of LRRK2, MMP-9, Cyclin A, Cyclin D1, Bcl-2, CDK4, Bax and p16 following transfection, western blot analysis was conducted. As depicted in Fig. 4, there was no significant difference observed regarding the protein expression levels of LRRK2, MMP-9, Cyclin A, Cyclin D1, Bcl-2, CDK4, Bax and p16 following transfection, while the protein expression levels of LRRK2, MMP-9, Cyclin A, Cyclin D1, Bcl-2, and CDK4 as well as the ratio of p-JNK/JNK were elevated, while those of Bax and p16 were decreased...
Figure 3. Reverse transcription-quantitative polymerase chain reaction demonstrated that, via the inactivation of the JNK signaling pathway, downregulation of LRRK2 elevates the mRNA expression levels of Bax and p16 and declines those of MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4 in thyroid cancer cells. (A) SW579 cell line. (B) IHH-4 cell line. The experiment was independently repeated in triplicate. *P<0.05 vs. the blank and NC groups; †P<0.05 vs. the si-LRRK2 group. The measurement data were expressed as the mean ± standard deviation and data among multiple groups were analyzed using one-way analysis of variance; LRRK2, leucine-rich repeat kinase 2; JNK, c-Jun N-terminal kinase; NC, negative control; si, small interfering; MMP-9, matrix metalloproteinase-9; CDK4, cyclin-dependent kinase 4; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X.

Figure 4. According to western blot analysis, silencing of LRRK2 increases the protein expression levels of Bax and p16, and declines those of MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4 by repressing the JNK signaling pathway in thyroid cancer cells. (A) Protein expression of associated proteins in the SW579 cell line. (B) The ratio of p-JNK/JNK in the SW579 cell line. (C) Protein bands of associated proteins in the SW579 cell line. (D) Protein expression of associated proteins in the IHH-4 cell line. (E) The ratio of p-JNK/JNK in the IHH-4 cell line. (F) Protein bands of associated proteins in the IHH-4 cell line. The experiment was independently repeated in triplicate. *P<0.05 vs. the blank and NC groups; †P<0.05 vs. the si-LRRK2 group. The measurement data were expressed as the mean ± standard deviation and data among multiple groups were analyzed using one-way analysis of variance. LRRK2, leucine-rich repeat kinase 2; p-JNK, phospho-c-Jun N-terminal kinase; NC, negative control; si, small interfering; MMP-9, matrix metalloproteinase-9; CDK4, cyclin-dependent kinase 4; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X.
were reduced in the pcDNA-LRRK2 group (P<0.05). The si-LRRK2, SP600125 and si-LRRK2 + SP600125 groups implicated opposite tendencies with the pcDNA-LRRK2 group (P<0.05). Compared with the si-LRRK2 group, the si-LRRK2 + SP600125 group exhibited significantly decreased protein expression of LRRK2, MMP-9, Cyclin A, Cyclin D1, Bcl-2, and CDK4 as well as the ratio of p-JNK/JNK, but significantly increased expression of Bax and p16 (P<0.05). The results in the SW579 and IHH-4 cell lines exhibited a consistent tendency. The results indicate that downregulated LRRK2 may elevate the protein expression levels of Bax and p16, and reduce MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4 protein expression levels as well as the ratio of p-JNK/JNK by inhibiting the JNK signaling pathway.

**Downregulated LRRK2 inhibits TC cell proliferation.** Subsequently, SRB staining was performed to detect cell viability. The results (Fig. 5A) demonstrated that SW579 cells had the same tendency as the IHH-4 cell line. There was no significant difference in TC cell viability between the blank and NC groups (P>0.05). Compared with the blank and NC groups, the pcDNA-LRRK2 group exhibited significantly enhanced cell viability, while the si-LRRK2, SP600125, and si-LRRK2 + SP600125 groups exhibited significantly restrained cell viability (P<0.05). The si-LRRK2 + SP600125 group exhibited suppressed cell viability, compared with the pcDNA-LRRK2 group (P<0.05). These data indicate that downregulated LRRK2 could inhibit cell viability in TC through suppressing the activation of the JNK signaling pathway.

**Repression of LRRK2 inhibits TC cell migration.** Subsequently, a scratch test was conducted to determine cell migration. As depicted in Fig. 6, the SW579 and IHH-4 cell lines had the same tendency. The blank and NC groups exhibited no significant difference in TC cell migration (P>0.05). The pcDNA-LRRK2 group exhibited significantly increased cell migration, and the si-LRRK2, SP600125 and si-LRRK2 + SP600125 groups exhibited significantly reduced cell migration, compared with the blank and NC groups (P<0.05). Cell migration was significantly reduced in the si-LRRK2 + SP600125 group, compared with the si-LRRK2 group (P<0.05). Therefore, reduced LRRK2 expression represses cell proliferation in TC cells via inactivating with the JNK signaling pathway.
with the si-LRRK2 group (P<0.05). These data provide evidence that low expression of LRRK2 could suppress JNK signaling pathway activation, thus inhibiting cell migration in TC cells.

Downregulation of LRRK2 promotes cell cycle arrest and apoptosis via inactivation of the JNK signaling pathway in TC cells. Subsequently, the effects of LRRK2 and the JNK signaling pathway on the cell cycle distribution of TC cells was investigated using flow cytometry. The results (Fig. 7) demonstrated that the SW579 and IHH-4 cell lines had the same tendency. The blank and NC groups revealed no significant difference in cell cycle arrest or apoptosis (P>0.05). Compared with the blank and NC groups, the pcDNA-LRRK2 group had significantly fewer cells arrested at the G0/G1 phase but significantly increased cells at the S phase, indicating a low apoptosis rate of TC cells; however, the si-LRRK2, SP600125 and si-LRRK2 + SP600125 groups exhibited significantly increased cells arrested at the G0/G1 phase but significantly fewer cells at the S phase, exhibiting increased apoptosis rates with the cell cycle arrest of TC cells (P<0.05). Collectively, decreased LRRK2 expression may enhance cell cycle arrest and apoptosis in TC cells by inhibiting the activation of the JNK signaling pathway.

Downregulated LRRK2 contributes to light blue fluorescence in TC cells with complete cell membrane and plentiful cytoplasm, and promotes positive staining signal. The morphology of cell apoptosis was observed under a fluorescence microscope (Fig. 8A). It was observed that the SW579 cell line had the same tendency as the IHH-4 cell line. Following staining with the DNA fluorescent dye Hoechst 33258, all groups exhibited cells with agglutinated and marginalized nuclear chromatin, as well as partial cells with apoptotic bodies, nuclear concentration and fragmentation and nuclear membrane that disappeared or bulged in the shape of vesicles. Apoptotic bodies were marginally blurry and crumpled and were notably smaller, compared with the peripheral normal nucleus with bright blue fluorescence. The si-LRRK2, SP600125 and si-LRRK2 + SP600125 groups had more complete cell membranes, plentiful cytoplasm, and round or nearly round nuclei with a uniform size and light blue fluorescence; compared with the fluorescence in the blank group, the bright blue fluorescence was significantly increased in the aforementioned three groups.

Results of TUNEL staining were observed under the fluorescence microscope (Fig. 8B-D). The SW579 cell line had the same trend as the IHH-4 cell line. In comparison with the blank and NC groups, the pCDNA-LRRK2 group
Flow cytometry demonstrated that low expression of LRRK2 inhibits the activation of the c-Jun N-terminal kinase signaling pathway, thus promoting cell cycle arrest and apoptosis in thyroid cancer cells. (A) Cell cycle distribution of the SW579 cell line in each group. (B) Histogram of cell cycle distribution of the SW579 cell line in each group. (C) Cell apoptosis rate of the SW579 cell line in each group. (D) Histogram of cell apoptosis rate of the SW579 cell line in each group. (E) Cell cycle distribution of the IHH-4 cell line in each group. (F) Histogram of cell cycle distribution of the IHH-4 cell line in each group. (G) Cell apoptosis rate of the IHH-4 cell line in each group. (H) Histogram of cell apoptosis rate of the IHH-4 cell line in each group. The experiment was independently repeated in triplicate.

*P<0.05 vs. the blank and NC groups; #P<0.05, vs. the si-LRRK2 group. The measurement data were expressed as the mean ± standard deviation and data among multiple groups were analyzed using one-way analysis of variance. LRRK2, leucine-rich repeat kinase 2; si, small interfering; NC, negative control.
had weakened positive staining signal, while the si-LRRK2, SP600125, si-LRRK2 + SP600125 groups exhibited promoted positive staining signal with increased apoptotic cells. Therefore, the conclusion can be drawn that cells exhibit light blue fluorescence with the complete cell membrane and plentiful cytoplasm, and promote positive staining signal owing to downregulation of LRRK2.

**Discussion**

**SP600125 exhibits no cytotoxicity.** The results demonstrated that after 24 h of treatment with SP600125 (1 and 10 µM), the positive rate of SW579 cells with trypan blue staining was <5%, indicating that SP600125 is not cytotoxic to these cells (Fig. 9).

**TC is a type of cancer accounting for ~1-2% of all human cancer types, while papillary and follicular TC are the two most common histological varieties (27). Among various treatment options, multi-kinase inhibitors are the most promising (28). In the present study, the effects of LRRK2 on TC cells were investigated. The results revealed that LRRK2 downregulation can enhance cell cycle arrest and apoptosis by inhibiting JNK signaling pathway activation in TC cells.**
Firstly, it was determined that the LRRK2 gene was expressed at a high level and phosphorylated the JNK signaling pathway in TC cells. LRRK2 expression was reported to be ubiquitous, and its expression levels were different among organs and tissues (29). A previous study provided evidence that the expression level of the LRRK2 gene was increased in the kidney, lung, and spleen, compared with in the brain (29). Similarly, when reacted with the mesenchymal-epithelial transition (MET) signaling pathway, the expression of the LRRK2 gene was previously demonstrated to be increased in papillary TC (19). Furthermore, targeting LRRK2 may be regarded as an appealing pharmacologic approach to complement MET inhibitors in patients with specific papillary tumors (19). The JNK signaling pathway is involved in cellular processes, including proliferation, differentiation and apoptosis, and is implicated in a number of diseases, including cancer, and neurological and immunological/inflammatory conditions (30). Activation of the JNK signaling pathway is involved in the cell apoptosis due to numerous stimuli in cancer types, including breast and ovarian cancer (31,32). LRRK2 has been previously demonstrated to be able to act as a functional kinase mediating the autophosphorylation or phosphorylation of generic kinase substrates (33). The JNK signaling pathway was reported to be highly phosphorylated in human cytomegalovirus in a previous study (34). Additionally, evidence has demonstrated that JNK phosphorylation facilitates apoptosis in a number of ovarian cancer cells (35). Published reports demonstrated that the proliferation, growth and invasiveness of TC cells could be inhibited or elevated through phosphorylation of different signaling pathways or genes, including the Akt signaling pathway or the CD44 gene (36,37).

Another observation of the present study was that repression of LRRK2 enhanced cell cycle arrest and apoptosis and suppressed cell migration and proliferation in TC cells, as indicated by the reduced expression of MMP-9, Cyclin A, Cyclin D1, Bcl-2 and CDK4, along with the increased expression of Bax and p16. In breast cancer, the protein expression levels of MMP-9 and Cyclin D1 were demonstrated to be decreased through downregulated metastasis-associated protein 1 via the RNAi pathway (38). The same tendency of Cyclin D1 and Cyclin D2 was determined in HepG2 and Hep3B cells through Notch1, which elevated the expression of Bax (39). Cyclin A and p16 are genes that regulate the cell cycle, and their upregulation has been respectively identified in colorectal and breast cancer (40,41). Cyclin D1 expression was reported to be positively associated with activation of the JNK pathway (42). CDK4 serves a pivotal role in G1-phase progression in oral squamous cell carcinoma via Cyclin D (43). LRRK2 has been detected in most immune cells, including T cells, B cells and various subtypes of monocytes (44). Reduced mutant (G2019S) LRRK2 was once reported to inhibit the mitogen-activated protein kinase 4-JNK-c-Jun pathway in PD (45,46). Repression of LRRK2 was demonstrated to allay microglial inflammatory responses (47,48). Furthermore, LRRK2 downregulation could result in a spectrum of developmental deviations combined with a neuronal loss (49). A recent study elucidated that the downregulation of tectonic I promoted cell cycle arrest and apoptosis, thus inhibiting cell...
proliferation in TC cells (50), an observation that is consistent with the data of the present study.

Accordingly, the present study illuminates potential molecular mechanisms by which LRRK2 silencing-forced inactivation of the JNK signaling pathway triggers cell cycle arrest and apoptosis in TC cells (Fig. 10). However, considering the inevitable limitations, including limited sample size, more detailed and large-scale studies are required in the future. Therefore, the present study provides a key target for the treatments of TC through the study of JNK inhibitors. However, further studies are required to elucidate the specific mechanisms by which JNK inhibitors ameliorate TC, and a larger sample size should be employed.

Acknowledgements
The authors would like to acknowledge the helpful comments on the present paper received from our reviewers.

Funding
The present study was supported by Scientific Research Program of Zhejiang Medical Association (grant no. 2015ZYC-A25).

Availability of data and materials
All of data and materials during the study are available from the corresponding author on reasonable request.

Authors' contributions
WJW, XHG and XC designed the study. XJC and QZ collated the data, and designed and developed the database. WJW and XHG conducted the data analyses and produced the initial draft of the manuscript. WJW, and XC wrote the main manuscript text. QZ prepared the figures. ZCJ revised it critically for important intellectual content. All authors have read and approved the final submitted manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References


